The Effects of BAY1193397 on Skin Capillary Blood Flow and Transcutaneous Oxygen Pressure
Status:
Completed
Trial end date:
2019-10-28
Target enrollment:
Participant gender:
Summary
The purpose of the study is to analyse skin blood flow in diabetic patients. The patients
receive a single dose of placebo, 1 mg BAY1193397, and 5 mg BAY1193397. The analysis of
safety and tolerability are secondary objectives of this study.